The initiative involves manufacturers providing drugs at international prices, with rebates and federal savings shared, and runs through 2030 to curb rising drug costs for Medicaid recipients
CMS Announces Participants in Landmark Medicaid Drug Payment Model to Bring Down Drug Costs
